content_top
43 companies, 1 interpreter! Insight, foresight
and recommendation 

Vericel Corporation (VCEL)

4.40
-0.05
(-1.12%)
Sep 11, 4:00PM EDT
content_middle

Aastrom Biosciences, Inc., a clinical-stage biotechnology company, focuses on the development of cell therapies for use in the treatment of severe chronic ischemic cardiovascular diseases. The company is developing a manufacturing technology platform, the Aastrom Replicell System, which enables the expansion of a various cell types, including the production of multicellular therapies expanded from an adult patient’s own bone marrow that can be delivered directly to damaged tissues. Its lead product candidate include ixmyelocel-T, to treat patients with severe chronic ischemic cardiovascular diseases, such as advanced heart failure due to dilated cardiomyopathy, the third leading cause of heart failure, and critical limb ischemia. The company was founded in 1989 and is headquartered in Ann Arbor, Michigan.

Previous Close: 
4.45
Open: 
4.50
Bid: 
4.40
Ask: 
4.50
1yr Target Price: 
6.59
Day's Range: 
4.40 - 4.55
52wk Range: 
2.00 - 4.70
Volume: 
464242
Average Daily Volume: 
476940
Market Capitalization: 
144.43M
Trailing Annual Dividend Yield: 
N/A
Shares Outstanding: 
32824000M
content_right